Arformoterol
Appearance
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Brovana |
Other names | Arformoterol tartrate (USAN US) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a602023 |
License data |
|
Routes of administration | Inhalation |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 52–65% |
Elimination half-life | 26 hours |
Identifiers | |
| |
CAS Number | |
Chemical and physical data | |
Formula | C19H24N2O4 |
Molar mass | 344.411 g·mol−1 |
| |
![]() ![]() |
Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).[1][2]
It is a long-acting β2 adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol.[1] It was approved for medical use in the United States in October 2006.[1] It is available as a generic medication.[3]
Medical uses
[edit]Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD).[1]
References
[edit]- ^ a b c d e "Brovana- arformoterol tartrate solution". DailyMed. 13 May 2021. Retrieved 4 March 2022.
- ^ Loh CH, Donohue JF, Ohar JA (March 2015). "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease". Expert Opinion on Drug Safety. 14 (3): 463–72. doi:10.1517/14740338.2015.998196. PMID 25563342. S2CID 7767810.
- ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
External links
[edit]- "Arformoterol". Drug Information Portal. U.S. National Library of Medicine.
- "Arformoterol tartrate". Drug Information Portal. U.S. National Library of Medicine.